Disufenton sodium

Disufenton sodium
Systematic (IUPAC) name

Disodium 4-[(Z)-(tert-butyl-oxidoazaniumylidene)methyl]benzene-1,3-disulfonate
Identifiers
ATC code	None
PubChem	CID 6440181
ChemSpider	28530805
UNII	7M1J3HN9VO^N
KEGG	D03875^Y
ChEMBL	CHEMBL1627056^N
Chemical data
Formula	C₁₁H₁₃NNa₂O₇S₂
Molar mass	381.33 g/mol
SMILES CC(C)(C)[N+](=Cc1ccc(cc1S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]
InChI InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2 Key:XLZOVRYBVCMCGL-UHFFFAOYSA-L
^NY (what is this?) (verify)

Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutylnitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial^[1]^[2] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".^[1] AstraZeneca then terminated the development programme.^[3] PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH ( AKA, NtBHA ) and its parent spin-trap MNP.

References

1 2 Lees, Kennedy R.; Zivin, Justin A.; Ashwood, Tim; Davalos, Antonio; Davis, Stephen M.; Diener, Hans-Christoph; Grotta, James; Lyden, Patrick; et al. (2006). "NXY-059 for Acute Ischemic Stroke". New England Journal of Medicine 354 (6): 588–600. doi:10.1056/NEJMoa052980. PMID 16467546.
↑ Lees, KR; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Lyden, P; Shuaib, A; Ashwood, T; et al. (2006). "Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial". Stroke; a journal of cerebral circulation 37 (12): 2970–8. doi:10.1161/01.STR.0000249410.91473.44. PMID 17068304.
↑ Renovis: Press Release

External links

AstraZeneca

Products	Anastrozole Atenolol Brompheniramine Budesonide Disufenton sodium Esomeprazole FluMist Gefitinib Goserelin Isosorbide mononitrate Motavizumab Omeprazole Palivizumab Propofol Rosuvastatin Tamoxifen Ticagrelor Vandetanib Ximelagatran Zafirlukast Zolmitriptan

Predecessors and acquired companies	Astra AB Cambridge Antibody Technology MedImmune Zeneca

People	Tom McKillop Louis Schweitzer

Category Commons

This article is issued from Wikipedia - version of the Thursday, July 23, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.